There is widespread variability in the interpretation of the labels "prospective" and "retrospective".
It is relevant to know in which order question formulation, data collection and analysis took place.
Should we:
Item 7: Describe the reference standard and its rationale.
Consideration:
The rationale for the reference standard is often not reported, and typically not provided in the methods section.
Should we:
Item 8: Describe technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard. technical specifications.
The relevance of technical information reported may differ between types of tests (e.g. imaging, laboratory, other).
Item 9: Describe definition of and rationale for the units, cutoffs and/or categories of the results of the index tests and the reference standard.
Consideration:
This item is ambiguous -accuracy does not depend on the unit of measurement, but may change with the cutoffs and categories chosen to classify test results.
Should we:
Item 10: Describe the number, training and expertise of the persons executing and reading the index tests and the reference standard. Keep this item as it is n m l k j Modify this item: remove "units" and invite authors to report whether cutoffs and/or categories were prespecified (our suggestion) n m l k j Should we:
Item 11: Describe whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.
Consideration:
There is widespread variability in the interpretation of the label "blind".
It is important to know what information is available to the readers of the tests. This item contains both a negative statement ("blinding") and a positive statement ("clinical information available").
Should we:
Item 12: Describe methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals). Consideration:
The nature of statistical methods to be reported seems unclear to many authors: methods for the accuracy statistics, or for the uncertainty, or both?
Should we:
Item 13: Describe methods for calculating test reproducibility, if done.
Consideration:
The word "reproducibility" is ambiguous. Estimating a test's reproducibility is not an element of most diagnostic accuracy studies.
Many studies refer to other publications or to the manufacturer for information on test reproducibility.
Should we:
Item 14: Report when study was done, including beginning and ending dates of recruitment. Consideration:
This item is almost always reported in the methods section, rarely in the results section, and refers to participant recruitment (item 4).
Item 15: Report clinical and demographic characteristics of the study population (e.g. age, sex, spectrum of presenting symptoms, comorbidity, current treatments, recruitment centers).
Consideration:
Depending on the type of test and target condition, there is a very large variety in suitable clinical and demographic characteristics reported in diagnostic accuracy studies.
Should we:
Item 16: Report the number of participants satisfying the criteria for inclusion that did or did not undergo the index tests and/or the reference standard; describe why participants failed to receive either test (a flow diagram is strongly recommended). Consideration: This is a lengthy and complex item.
Flow diagrams were strongly recommended in STARD, but these are only used in a minority of studies.
Item 17: Report time interval from the index tests to the reference standard, and any treatment administered between.
Consideration:
We did not observe major issues with this item.
Should we:
Item 18: Report distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition. 
Consideration:
Long and confusing wording. Indeterminate and missing results are almost never reported in cross tabulations.
It is important to know how indeterminate results, missing responses and outliers were handled, but this is already discussed in item 22.
Should we:
Item 20: Report any adverse events from performing the index tests or the reference standard. Consideration:
Adverse events are rarely reported in diagnostic accuracy studies; such studies typically lack the power and design to estimate adverse event rates.
Many tests do not have intrinsic adverse events.

Should we:
Item 21: Report estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).
Consideration:
Should we:
Item 22: Report how indeterminate results, missing responses and outliers of the index tests were handled. Authors should be encouraged to plan ahead how to handle indeterminate results, missing responses and outliers in their study protocol.
Item 23: Report estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.
Consideration:
Test accuracy may vary across subgroups but many diagnostic accuracy studies lack the power to detect such variations.
Variability is often not reported.
Multiple subgroup analyses can increase the risk of falsepositive findings.
Should we:
Item 24: Report estimates of test reproducibility, if done. Consideration:
The word "reproducibility" is ambiguous.
Estimating a test's reproducibility is not an element of most diagnostic accuracy studies.
Item 25: Discuss the clinical applicability of the study findings.
Consideration:
This item is rather vague, general and not specific for diagnostic accuracy studies.
Many reports of test accuracy studies offer generous and optimistic interpretations of the study findings, with strong recommendations for practice.
Should we:
Keep this item as it is n m l k j The following items and issues were identified based on our literature review and comparisons between STARD and other reporting guidelines.
Your comments are always welcome and will be taken into account in the preparations for the second round of the survey.
This survey is not anonymous.
Please enter your first name and last name.
Sample size
Consideration: Sample size calculations are rarely reported in diagnostic accuracy studies.
Should STARD recommend reporting the method and rationale for the study sample size calculation?
Cutoffs for continuous tests
Welcome to the first round of the STARD update survey. Many diagnostic accuracy studies report area under the receiver operator curve (AUC ROC).
PROPOSALS FOR NEW ITEMS PROPOSALS FOR NEW ITEMS
Without accuracy estimates at specific cutoffs, such a result is difficult to apply.
Should STARD recommend reporting at least one cutoff when reporting AUCROC?
Additional information
Scope of STARD
PROPOSALS FOR NEW ITEMS Consideration:
There is a movement towards more openness and transparency in health research in general. This is not specific for test accuracy studies.
Should STARD recommend reporting... Consideration:
STARD was originally targeted at "diagnostic accuracy studies".
Many other studies also report accuracy estimates, as an additional aim.
Should the applicability of STARD be rephrased, from "diagnostic accuracy studies" to "studies reporting diagnostic accuracy"?
Scope of STARD
Consideration:
STARD was originally targeted at "diagnostic accuracy studies", which are cross sectional.
In practice, we also see diagnostic studies with socalled "delayed verification", and other studies reporting on prognostic accuracy.
Should the applicability of STARD be extended to prognostic accuracy studies? Medical tests are not just used for diagnosis and prognosis, but also for other purposes, such as screening, monitoring or treatment selection.
Many, if not all, STARD items also apply to studies evaluating the accuracy of such tests.
Should the applicability of STARD be rephrased, from "diagnostic accuracy" to "(clinical) test accuracy"?
Scope of STARD
Consideration:
The emphasis in STARD was on studies of a single (index) test, but the principles also apply to evaluations of the accuracy of multiple tests, combinations of tests, and multivariable models and rules.
Should the applicability of STARD be rephrased, e.g. in terms of "all evaluations of the accuracy of one or more tests, or combinations of test results and/or other variables"? Consideration:
There is a wide variety of terms used to describe elements of a diagnostic accuracy study.
Should STARD recommend preferred terms for indicating... 
